$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
When will Blinatumomab be included in medical insurance?
2026-02-01 22:25:32
Check Details
Can Blinatumomab be reimbursed by medical insurance?
2026-02-01 22:25:32
Check Details
Is Blinatumomab a targeted drug?
2026-02-01 22:25:32
Check Details
Chinese instructions for Blinatumomab
2026-02-01 22:25:32
Check Details
Blinatumomab treatment options
2026-02-01 22:25:32
Check Details
Blinatumomab Cure Rate
2026-02-01 22:25:32
Check Details
Can Blinatumomab prevent leukemia from coming back?
2026-02-01 22:25:32
Check Details
Blinatumomab dosage and usage
2026-02-01 22:25:32
Check Details
The effect of Blinatumomab chemotherapy on acute lymphoblastic leukemia
2026-02-01 22:25:32
Check Details
Do I have to take Blinatumomab for 14 days?
2026-02-01 22:25:32
Check Details
Survival with Blinatumomab in acute lymphoblastic leukemia
2026-02-01 22:25:32
Check Details
How many days does a course of Blinatumomab last?
2026-02-01 22:25:32
Check Details
1
2
...
243
244
245
246
247
248
249
...
10221
10222
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Macitentan Guide: Dietary Interactions, Contraindications, and Reproductive Safety Protocols
2
Global Update 2026: Selumetinib (KOSELUGO) Expands Indication to Adult NF1-PN and Clinical Management Strategies
3
Lenvatinib Safety Guide: Baseline Assessment & Adverse Reaction Management
4
Donidalorsen (DAWNZERA®) Side Effects and Safety Management Guide
5
Inluriyo (Imlunestrant): Oral SERD for ER+/HER2- Breast Cancer with ESR1 Mutations
6
Idelalisib: Oral PI3Kδ Inhibitor for Relapsed/Refractory Hematologic Malignancies
7
Lorlatinib (Lorviqua): Oral Targeted Therapy for ALK-Positive Advanced Non-Small Cell Lung Cancer
8
Elafibranor for Primary Biliary Cholangitis: Indication, Dosing, and Safety Overview
9
AbbVie’s TEPKINLY (epcoritamab) Plus R² Granted EU Approval for Relapsed/Refractory Follicular Lymphoma
10
FDA Approves Ibrance for New Maintenance Indication in HR+/HER2+ Breast Cancer
11
FDA Approves Trodelvy for Two First-Line Indications, Redefining Advanced Triple-Negative Breast Cancer Care
12
Cabozantinib: A Pan-Targeted TKI in Modern Oncology Practice